Nature of the Business and Going Concern (Details)			3 Months Ended
	Mar. 31, 2021 USD ($) employee $ / shares shares	May 15, 2020 USD ($)	Mar. 31, 2021 USD ($) employee segment product $ / shares	May 24, 2021 USD ($)	Dec. 31, 2020 USD ($) employee	Sep. 30, 2020 USD ($)	Jun. 19, 2020 employee	Mar. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 13, 2018 USD ($)
Summary of Significant Accounting Policies Details [Line Items]
Segments | segment			1
Cash, cash equivalents and restricted cash in the statement of cash flows | $	$ 28,310,000		$ 28,310,000		$ 6,712,000			$ 11,702,000	$ 16,182,000
Cash and cash equivalents | $	27,454,000		27,454,000		5,946,000			$ 11,028,000
Aggregate principal amount | $	$ 108,792,000		$ 108,792,000		$ 181,580,000
Number of terminated employees | employee							53
Number of furloughed employees | employee							15
Number of employees | employee	146		146		153
Employee base, percentage decrease in recruitment	4.60%		4.60%
Proceeds received under PPP | $		$ 3,400,000
Stated interest rate		1.00%
Subsequent Event
Summary of Significant Accounting Policies Details [Line Items]
Cash and cash equivalents | $				$ 24,600,000
United States
Summary of Significant Accounting Policies Details [Line Items]
Pharmaceutical products, number of generic products marketed			37
Pharmaceutical products, number of branded generic products marketed			2
Pharmaceutical products, number of topical generic products with approvals			36
Number of Abbreviated New Drug Applications on topical products			7
Number of New Drug Application Prior Approval Supplements for sterile injectable products, awaiting approval			3
Ophthalmic products, number of generic injectable products marketed			25
Ophthalmic products, number of generic topical products marketed			3
Ophthalmic products, number of generic products marketed			3
Canada
Summary of Significant Accounting Policies Details [Line Items]
Number of Abbreviated New Drug Applications on topical products			1
At-the-Market Offering
Summary of Significant Accounting Policies Details [Line Items]
Stock issued during period, shares, new issues (in shares) | shares	38,712,036
Sale of stock, price per share (usd per share) | $ / shares	$ 0.993		$ 0.993
Term Loan
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $						$ 83,500,000
Term Loan | Line of Credit
Summary of Significant Accounting Policies Details [Line Items]
Aggregate principal amount | $										$ 80,000,000.0